Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows tenofovir disoproxil fumarate improves mother-to-child transmission rates in pregnant women with high HBV DNA levels, indicating favorable safety profile.
TDF tablets can prevent MTCT of HBV in pregnant women with high HBV DNA loads. The treatment increases the seroconversion rates of HBV DNA, HBeAg, and HBsAg in mothers and infants, and shows a favorable safety profile without severe adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: